PARTICIPANT LIST
Albanese, Alberto,. Istituto di Neurologia, Universita Cattolica, Largo A. Gemelli, 8, 00168 Rom~, Italy
Ansell, G. Brian, Department of Pharmacology, University of Birmingham, The Medical School, Birmingham B15 2TJ, UK
Aquilonius, Sten-Magnus, Department of Neurology, University Hospital, S-750 14 Uppsala, Sweden
Barker, Louis A., Department of Pharmacology, The Mount Sip.ai Medical Center, New York, New York, 10029 USA
Bartfai, Tamas, Department of Biochemistry, Arrhenius Laboratory, University of Stockholm, S-1069l, Stockholm, Sweden
Bartolini, Alessandro, Department of Pharmacology, University of Florence, 50134, Florence, Italy
Beani, Lorenzo, Department of Pharmacology, School of Medicine, University of Ferrara, 44100 Ferrara, Italy
Bianchi, Beani, Clety, Department of Pharmacology, School of Pharmacy, University of Ferrara, 44100 Ferrara, Italy
Bigl, Volker, Abteilung fur Neurochemie, Karl Mark Universita t, Karl-Marx-Stadter Str. 50, DDR-7039 Leipzig, Germany
Birdsall, Nigel, J .M., National Institute for Medical Res·earch, The Ridgeway, Mill Hill, London NW? 1AA, UK
Bisso, Guillermo Mario, Laboratorio di Fa,rmacologia, :R,ep. Farmacologia Biochimica, Istituto Superi.ore di Sanita, Viale Regina Elena 299, Rome, Italy
Blass, John, Burke Rehabilitation Center, 385 Mammaroneck Avenue, White Plains, New York 10605, USA
963
964
Bonetti, Anna Chiara, Fidia Research Labora.tories, 35031 Abano Terme, Italy
PARTICIPANTS LIST
Butcher, Larry L., Department of Psychology and The Brain Research Institute, University of California, Los Angeles, California 90024, USA
Ca1derini, Gabriella, Fidia Research Laboratories, 35031 Abano Terme, Italy
Carmignoto, Giorgio, Fidia Research Laboratories, 35031 Abano Terme, Italy
Casamenti, Fiorella, Department of Pharmacology, School of Medicine, University of Florence, 50134 Florence, Italy
Ceccarelli, Bruno, Department of Pharmacology, University o£, Milan, 20129 Milan, Italy
Cheney, Darwin L., Laboratory of Preclinical Pharmacology, NIMH, St. Elizabeth's Hospital, Wa.shington, D.C. 20032, USA
Collier, Brian, Department of Pharmacology, McIntyre Medical Sciences Bldg., McGill University, Quebec H3G lYo, Canada
Consolo Ladinksy, Silvana, Mario Negri Institute of Pharmacological Research, 20157 Milan, Italy
Cooper, Jack R., Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, Connecticut 06510 USA
Corradetti, Renato, Department of Pharmacology, School of Medicine, University of Florence, 50134 Florence, Italy
Corthay, Jacqueline, Department of Pharmacology, 20 rue de l' E.co1e de Medicine, 1211 Geneva 4, Switzerland
Costa, Erminio, Laboratory of Preclinical Pharmacology, NIMH, St. Elizabeth's Hospital, Washington, D.C. 20032, USA
Dahlbom, Richard, Department of Pharmaceutical Chemistry, University of Uppsa1a, S-750 Uppsala, Sweden
Davis, Kenneth, Bronx Veteran's ADministra.tion Hospital, Bronx, New York 10468 USA
De Biasi, Silvia, Fidia Research Laboratori.es, 35031 Aliano Terme, Italy
PARTICIPANTS LIST
DiGiamberardino, Luigi, CEA de Sac1ay~DB/LLPC, Boite Posta1e 2, 91190 Gif-sur-Yvette, France
Dimpfe1, W., Fidia Research Laboratories, 35031 Abano Te.rm.e, Italy
Domino, Edward F., Department of Pharmacology, University of Michigan, Medical School, Ann Arbor, Michigan 45105 USA
Dowdall, Michael J., Department of Biochemistry, The Medical School, University of Nottingham, Nottingham, UK
965
Dun, Nae J., Department of Pharmacology, Loyola University Stritch School of Medicine, 2160 S. First Avenue, Maywood, Illinois 60153 USA
Dunant, Yves, Department of Pharmacology, 20 rue de 1tEco1e de Medecine, 1211 Geneva 4, Switzerland
Eckernas, Sven-Ake, Department of Neurology, University Hospital, S-750 14 Uppsa1a, Sweden
Fesce, R., Department of Pharmacology, University of Milan, 20129 Milan, Italy
Ferrari, Giovanna, Fidia Research Laboratories, 35031 Abano TeJ;"me, Italy
Fibiger, Hans C., University of British Columbia, Department of Psychiatry, Vancouver V6T 1W5, Canada
Filogamo, Guido, Istituto di. Anatomia Umana Norma1e, University of Torino 10126 Torino, Italy
Flentge, F., Department of Biological Psychiatry, Academisch Ziekenhuis Groningen, 9700 RB Groningen, The Netherlands
Fonnum, Frode, Department of Toxicology, Norwegian Def:ence Research Establishment, N-2007, Kje11er, Norway
Froissart, Chantal, Certre de Neurochemie du CNRS, 11 rue Humann 67085 Strasbourg cedex, France
Fu1pius, Bernard W., University of Geneva, Department of Biochemistry, Sciences II, 1211 Geneva, Switzerland
Galli, Alessandro, Department of Pharmacology, School of: Medicine, University of Florence 50134, Florence, Italy
Giacobini, Ezio, Department of Biobehaviora1 Sciences U~154, University of Connecticut, Storrs, Connecticut 0626.8 USA
966 PARTICIPANTS LIST
Gibson, Gary, Department of Neurology, Cornell Medical College, Burke Rehabilitation Center, 785 Mamaroneck Avenue, White Plains, New York, 10605 USA
Gillin, J. Christian, National Institute of Mental llealth, NIH, Bethesda, Maryland 20205 USA
Gorio, Alfredo, Fidia Research Laboratories, 35031 Abano Terme, Italy
Han in , Israel, University of Pittsburgh, School of Medicine, Western Psychiatric Institute and Clinic, 3811 O'Hara Street, Pittsburgh, Pennsylvania 15261 USA
Haubrich, Dean R., Merck Institute for Therapeutic Research, West Point, Pennsylvania 19486 USA
Hedlund, Britta, Department of Biochemistry, Arrhenius Laboratory, University of Stockholm, S-1069l Stockholm, Sweden
Heilbronn, Edith, Unit of Neurochemistry and Neurotoxicology, University of Stockholm, c/o FOA Ursvik, S-104 SO Stockholm, Sweden
Hemsworth, Brain A., University of Aston, Department of Pharmacy, Gosta Green, Birmingham, B4 7ET, UK
Hersh, Louis B., Department of Biochemistry, The University of Texas, Health Science Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235 USA
Hopff, Wolfgang, Department of Pharmacology, University of Zurich, Gloriastasse 32, CH-8005, Zurich, Switzerland
Howard, Bruce, Department of Biological Chemistry, School of Medicine, University of California, Los Angeles, California 90024 USA
Israel, Maurice, CNRS, Laboratory of Cellular Neurobiology, Department of Neurochemistry, 91190 Gif-sur-Yvette, France
Jenden, Donald J., Department of Pharmacology, School of Medicine, University of California, Los Angeles, California 90024 USA
Jape, Richard S., Department of Pharmacology, School of Medicine University of California, Los Angeles, California 90Q24 USA
Karczmar, Alexander, G., Loyola University Stritch School of Medicine, Department of Pharmacology, Maywood, Illi.nois 60153 USA
PARTICIPANTS LIST
Kewitz, K., Freie Universitat Berlin, Institut fur Klinische Pharmakologie, Hindenburgdamm 30, D-1000 Berlin 45 Germany
967
Kharkevich, Dimitry A., Department of Pharmacology, First Medical Institute, 2/6 B. Pirogovskaja St., Moscow 1194R'} TJSSR
Kilbinger, Heinz, Department of Pharmacology, University of Mainz, D-6500 Mainz, Germany
Kimura, Hirosh, Kinsman Laboratory of Neurological Research, Department of Psychiatry, University of British Columbia, Vancouver, Canada
Koelle, George B., Department of Pharmacology, School of Medicine University of Pennsylvania, Philadelphis, Pennsylvania 19174 USA
Koenig, Herbert, Universite P. et M. Curie, Laboratoire de Neurocytologie, 7 Quai St. Bernard, Bat A/3c, 75005 Paris, France
Lotas, A.M., Department of Pharmacology, Univesrity of London, Kings College, The Strand, London WC2R 2LS, UK
Kuhar, Michael J., Department of Pharmacology, John Hopkins University, School of Medicine, 725 N. Wolfe Street, Baltimore, Maryland 21205 USA
Ladinsky, Herbert, Mario Negri Institute of Pharmacological Research, 20157 Milan, Italy
Leon, Alberta, Fidia Research Laboratories, 35031 Abano Terme, Italy
Lo Conte, Giovanni, Department of Pharmacology, School of Medicine, University of Florence, 50134 Florence, Italy
Loffelholz, Konrad, Department of Pharmacology, University of Mainz, Obere Zahlbacher Strasse 67, 6500 Mainz, Germany
Longo, Vincenzo, Istituto Superiore di Sanita, Viale Regina Elena 299, 00100 Rome, Italy
Lowenadler, Bjorn, Department of Neurochemistry and Neurotoxicology, University of Stockholm, c.o FOA Ursvik, S-104 50 Stockholm, Sweden
Lqumani, Yunas A., Max-Planck-Institut, Biophysical Chemistry, Postfach 968, Gottingen, Germany
M.-~ 1mb erg , Aiello, Petra, Department of Pharmacology, University of Florence, 50134 Florence, Italy
968 PARTICIPANTS LIST
Ma1the-Sorenssen, Didrik, Division of Toxicology, Norwegian Defence Research Establishment, N-2007 Kje11er, Norway
Manaranche, M., CNRS, Laboratory of Cellular Neurobiology, Department of Neurochemistry, 91190 Gif-sur-Yvette, France
Mantovani, Piero, Department of Pharmacology, School of Medicine, University of Florence, 50134 Florence, Italy
Marchbanks, Roger M., Department of Biochemistry, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK
Marchi, Mario, Department of Biobaviora1 Sciences U-154, University of Connecticut, Storrs, Connecticut 06268 USA
Massare11i, Raffaele, CNRS, Center of Neurochemistry, 11 rue Humann. 67085 Strasbourg cedex, France
Mautner, Henry G., Department of Biochemistry and Pharmacology, School of Medicine, Tufts University, 136 Harrison Avenue, Boston, Massachusetts 02111 USA
Michalek, Moricca Hanna, Laboratorio di Farmaco1ogia, Rep. Farmaco1ogia biochimica, Instituto Superiore di Sanita, Via1e Regina Elena 299, 00100 Rome, Italy
Mittag, Tom, Pharmacology Department, Mt. Sinai School of Medicine, One Gustave Levy Place, New York, New York 10Q29 USA
Molenaar, Peter C., Department of Pharmacology, Sy1vius Laboratories, University of Leiden, 72 Wassenaarseweg, Leiden, The Netherlands
Moroni, F1avio, Department of Pharmacology, School of Medicine, University of Florence, 50134 Florence, Italy
Neal, J., Department of Pharmacology, School of Pharmacy, 29 Brunswick Square, London we1, UK
Nordberg, Agneta, Department of Pharmacology, University of Uppsa1a, Box 578, 75123 Uppsa1a, Sweden
Oderfe1d-Nowak, Barbara, Institute of Experimental Biology, Polish Academy of Sciences, Pasteur 8, 02093 Warsaw, Poland
Paggi, Paola, Institute of General Physiology, University of Rome, 00100 Rome, Italy
Pauling, Peter, Chemistry Department, University College London, 20 Gordon Street. London UCI. UK
PARTICIPANTS LIST 969
Pedata, Felicita, Department of Pharmacology, School of Medicine, University of Florence, 50134 Florence, Italy
Pedigo, Norman W., Department of Pharmacology, University of Arizona Health Sciences Center, Tucson, Arizona 85724 USA
Pepeu, Giancarlo, Department of Pharmacology, School of Medicine, University of Florence, 50134 Florence, Italy
Perri, Virgilio, Institute of General Physiology, University of Ferrara, Via L. Borsari 46, 44100 Ferrara, Italy
Piazza Bartolini, Roselia, Department of Pharmacology, University of Florence, 50134 Florence, Italy
Polak, Robert, Medical Biology Laboratories, TNO, Ryswyk, The Netherlands
Procellati, Giuseepe, Institute of Chemical Biology, University of Perugia, 06100 Perugia, Italy
Prince, Alan Keith, Department of Pharmacology, University of London, Kings College, The Strand, London WC2R 2LS, UK
Racagni, Giorgio, Institute of Pharmacology and Pharmacognosia, University of Milan, 20129 Milan, Italy
Reynolds, R., Department of Pharmacology, Univesrity of London, Kings College, The Strand, London WC2R 2LS, UK
Renzi, Giovanni, Department of Pharmaceutical Chemistry, School of Pharmacy, University of Florence, 50121 Florence, Italy
Richardson, G. Peter, Max-Planck-Institut, Biophysical Chemistry, Postfach 968, 34 Gottingen, Germany
Riggio, G., Department of Pharmacology, University of Zurich, Gloriastrasse 32, CH-8006 Zurich, Switzerland
Robinson, Susan, Department of Pharmacology, College of Medicine, Texas A&M University, College Station, Texas 77843, USA
Scatton, Bernard, Synthelabo-LERS, 31 Avenue Paul-Vaillant Coutorier, 92220 Bagneux, France
Siniscalchi, Rossi, Anna, Department of Pharmacology, School of Medicine, University of Ferrara, 44100 Ferrara, Italy
Sitaram, Nastrai, National Institute of Mental Health, NIH, Bldg. 10, Room 3N224, Bethesda, Haryland 20014, USA
970 PARTICIPANTS LIST
Sorbi, Sandro, Neurol.ogical Clinic, School of Medicine, University of Florence, 50134 Florence, Italy
Spanner, Sheila, Go, Department of Pharmacology, The Medical School, University of Birmingham, Birmingham B15 2TJ, UK
Stadler, Herbert, Max-Planck-Institut, Biophysical Chemistry, Postfach 968, 34 Gottingen, Germany
Stavinoha, William Bo, The University of Texas Medical School, Department of Pharmacology, San Antonio, Texas, 78284, USA
Suszkiw, Janus Bo, The Biological Sciences Group, The University of Connecticut, Storrs, Connecticut, 06268 USA
Szerb, John Co, Department of Physiology and Biophysics, Dalhousie University, Halifax, Nova Scotia, B3H 4H7 Canada
Tanganelli, Sergio, Department of Pharmacology, University of Ferrara, 44100 Ferrara, Italy
Teolato, Sandra, Fidia Research Laboratories, 85031 Abano Terme, Italy
Tirelli, Silvia, Mario Negro Institute of Pharmacological Research, Via Eritrea 62, Milan, Italy
Toffano, Gino, Fidia Research Laboratories, 35031 Abano Terme, Italy
Toschi, Go, Institute of General Physiology, University of Rome, 00100 Rome, Italy
Tucek, Stanislav, Academy of Sciences, Insitute of Physiology, Videnska 1083, 14220 Prague, Czechoslovakia
Ulas, Jolanta, Nencki Institute of Experimental Biology, 3 Pasteur Strasse, 02093 Warsaw, Poland
Vizi, Sylvester, Department of Pharmacology, Semmelweis University of Medicine, H-1445 Budapest, Hungary
Wachtler, Klaus, Institut fur Zoologie, Der Tierartlishen Hochschule, 3 Hannover, Germany
Wahlstrom, Goran, University of Umea, Department of Pharmacology, S-90l,87 Umea, Sweden
Wecker, Lynn, Department of Pharmacology, Louisiana State University Medical Center, New Orleans, Louisiana 70112 USA
PARTICIPANTS LIST 971
Weiler, Molly, Laboratory for Neurochemistry, Max-Planck-Institut for Biophysical Chemistry, D-3400 Gottingen, Germany
Wenk, Hartmut, Abt. Neurochemie, Paul F1echsig Institut Hirnforschung, Karl Marx Stadtea Strasse 50, DDR-7039, Leipzig, Germany
Wessler, Ignaz, Department of Pharmacology, University of Mainz, D-6500, Mainz, Germany
Whittaker, Victor P., Laboratory for Neurochemistry, Max-PlanckInstitut for Biophysical Chemistry, D-3400 Gottingen, Germany
Wong, Tuen Yee, CNRS, Center for Neurochemistry, rue Humann, 67085 Strasbourg cedex, France
Wood, Paul L., Department of Pharmacology, Merck Frosst Laboratories, P.O. Box 1005, Pointe Claire-Dorval, Quebec H9R 4p8 Canada
Zimmerman, Herbert, Laboratory for Neurochemistry, Max-PlanckInstitute for Biophysical Chemistry, D-3400 Gottingen, Germany
Zsi11a, G., Department of Pharmacology, Semmelweis University of Medicine, H-1445 Budapest, Hungary
CONTRIBUTOR INDEX
Albanese, A., 723 Aloisi, F., 833 Ansell, G.B., 393 Aprison, M.H., 739 Aquilonius, S.M., 871, 879 Bak, 1.J., 531 Barker, L.A., 475 Bartfai, T., 579 Bartholini, G., 771 Battistella, A., 601 Beani, L., 763 Belluzzi, 0., 119 Berrie, C.P., 595 Bianchi, C., 763 Biesold, D., 673 Bigl, V., 673 Biondi, C., 119 Birdsall, N.J.M., 587, 595 Bisso, G.M., 847 Blass, J.P., 921 Blendy, J., 947 Bolzoni, L., 153 Bonetti, A.C., 601 Borasio, P.G., 119 Burgen, A.S.V., 595 Butcher, L.L., 723 Butcher, S.H., 723 Brunetti, M., 377 Calderini, G., 601 Capuzzo, A., 119 Carmignoto, G., 221 Casamenti, F., 685 Cheney, D.L., 705, 715, 825 Collier, B., 97 Consolo, S., 781 Cooper, J.R., 521 Corthay, J., 287, 321
973
Costa, E., 143, 705, 715, 825 Couraud, J.Y., 387 Cuenoud, S., 333 Dahlbom, R., 621 Davis, B.M., 929 Davis, K.L., 929 Davis, R., 127 Demetriou, S.K., 891 DeNigris, Y., 929 Dewey, W.L., 795 di Giamberardino, L., 377, 387 Dolezal, V., 415 Domino, E.F., 891 Dowdall, M.J., 249 Dowe, G.H.C., 235 Droz, B., 377 Duffy, T.E., 443, 921 Dun, N.J., 109 Dunant, Y., 287, 321 Eckernas, S.A., 871, 879 Eder, L., 287 Ehlert, F.J., 609 Ferretti, M.E., 119 Fibiger, H.C., 663 Filogamo, G., 85 Finesso, M., 221 Fonnum, F., 569 Forloni, G.L., 781 Fretten, P., 249 Froissart, C., 91 Fucek, F., 8'91 Fulpius,.B.W.,333 Garelli, M., 659 Gerber, N.H., 425 Gershon, E.S., 947 Giacobini, E., 1, 25 Giacobini-Robecchi, M.G., 659
974
Gibson, G.E., 443, 921 Gillin, J.C., 937, 947 Giompres, P., 261, 301 Goldberg, A.M., 451 Gorio, A., 221 Guidotti, A., 143 Hammar, R., 595 Hanbauer, I., 143 Han in , I., 901, 937 !iartvig, P., 879 Haubrich, D.R., 425 Hedlund, B., 579, 647 Hei1bronn, E., 343 Hexum, T., 143 Himme1hoch, J.M., 901 Hofmann, A.A., 323 Hopff, W .H., 323 Horvath, T.H., 929 Howard, B.D., 133 Hulme, E.C., 595 Israel, M., 215, 273 Jenden, D.J., 497, 531 Jope, R.S., 497 Jumblatt, J.E., 367 Kalaria, R.N., 73 Karczmar, A.G •• 109, 853 Kewitz, H., 405 Kharkevich. D.A .• 351 Kilbinger, H., 169, 235 Kumura, H., 695 Koelle, G.B., 127 Koelle, W.A., 127 Koenig, H.L., 377 Koff, U., 901 Kotas, A.M., 73, 469 Krammer, C., 937 Kr enz, W. D., 47 Kruel, R., 169 Ksiezak, H.J., 443 Kuhar, M.J., 587 Kupfer, D.J., 901 Ladinsky, H., 781 Larsson, C., 639 Lefvert, A.K., 333 Lehmann, J., 663 Leon, A., 221 Lindmar, R., 159 Lindstrom, B., 879 Lo Conte, G., 685
CONTRIBUTOR INDEX
Loctin, F., 287, 321 Loffelholz, K., 159 Longo, V.G., 833 Lowenadler, B., 343 Luqmani, Y.A., 301, 307 Lund-Karlsen, R., 569 Mallinger, A.G., 901 Manaranche, R., 215 Marchbanks, R.M., 489 Marchi, M., 1, 25 Marini, P., 221 Marquis, J.K., 367 Massarelli, R., 91, 511 Massey, S.C., 555 Mathews, B., 891 Mautner, H.G., 367 McGeer, E.G., 695 McGeer, P.L., 695 Melega, W.P., 133 Meneguz, A., 153, 847 Meyer, E.M., 521 Meyer, U., 673 Michalek, H., 847 Miledi, R., 197, 205 Misgeld, U., 531 Mittag, T.W., 541 Mohs, R.C., 929 Milenaar, P.C., 197, 205 Moore, A.M., 947 Neal, M.J., 555 Neil, J.F., 901 Nordberg, A., 639, 809, 819 Nordstrom, 0., 579 Nurnberger, J.I. Jr., 847 Oderfeld-Nowak, B., 739 Opsahl, M., 569 Opstad, P.K., 569 o t Regan, S., 97 Osterman, P.O., 879 Paggi, P., 153 Pedata, F., 685 Pedigo, N.W., 795 Peng, J.H., 695 Pepeu, G., 685 Perri, V., 119 Pflueger, A.B., 425 P1eul, 0., 405 Plum, F., 921 Polak, R.L., 197, 205
CONTRIBUTOR INDEX
Porcellati, G., 377 Pouch, W.P., 425 Prince, A.K., 73, 463, 469 Revuelta, A.V., 825 Reynolds, R., 73, 463 Richard, K.K., 127 Ricny, J., 415 Riggio, G., 323 Robinson, S.E., 705 Roeske, W.R., 609 Rosenberg, G.S., 929 Ruch, G.A., 127 Saiani, 1., 143 Samoilov, D.N., 351 Sanville, U.J., 127 Scotti de Carolis, A., 833 Scatton, B., 771 Segal, M., 781 Shorr, V.A., 351 Sisto-Daneo, L., 85 Sitaram, N., 937., 947 Skoldinov, A.P., 351 Soli, N.E., 569 Sorbi, S., 685 Spanner, S.G., 393 Spiker, D.G., 901 Stadler, R., 241 Stalberg, E., 879 Stockton, J., 595 Suszkiw, J.B., 313 Szerb, J.C., 177 Ta it, S. K., 891 Tanganelli,zS., 763 Tashiro, T., 47 Teolato, S., 601
Thieffry, M., 215 Tirelli, A.S., 781 Toffano, G., 601 Toyka, K., 343 Tredese, L., 221 Trevisani, A., 119 Tucek, S., 415 Uden, A., 579 Ulas, J., 841 Vanskiver, C., 947 Vizi, E.S., 187 Wachtler, V.P., 4, 47, 59 Wahlstrom, G., 809, 819 Walker, J. H., 653 Wamsley, J.K., 587 Waser, P.G., 323 Wecker, L., 451 Weide, W., 159 Weiler, M.H., 531 Weingartner, H., 937 Wenk. H., 673 Wessler, l. 169 Westlind, A., 579
975
Whittaker, V.P., 47,235,261,307 Witzmann, V., 47, 653 Wojcik, M., 841 Wong, P.T.H., 73 Wong, T.Y., 511 Wood, P.L., 715 Woolf, N.J., 723 Yamamura, H.I., 609 Yang, H.Y.T., 143 Zanoni, R., 221 Zarbin, M.A., 587 Zimmermann, H., 261
SUBJECT INDEX
A23187 on ACh release, 523,580
Abstinence after barbital, 819
Acetate in ACh synthesis, 262,314,415
N-Acety1ated amino acids, 415 Acety1carnitine
and acetate incorporation, 314 in ACh synthesis; 416
Acetyl CoA endogenous source, 503 from acety1carnitine, 314 from citrate, 415 from glucose, 416,490 from pyruvate, 415,501 in ACh synthesis, 415
Acetyl group source of, 415
Acetyl-8-methylcholine, 549,613 Acetyltriethylcholine, 309 Acetylmonoethylcholine, 274 ACh
and antinociception, 796 and binding, 613 and high affinity transport, 475 assays for, 715,782 bound, 276,291 cytoplasmic, 294,490 free, 294 in brain through phylogeny, 62 in neuronal cultures, 516 in sympathetic and para-
sympathetic ganglia, 9 interactions, 875 in the cornea, 542 in the retina, 543 in the striatum, 734 labile bound, stabile bound, 507 level and barbital, 811
and GABAergic drugs, 771 and neuropeptides, 715 and oxotremorine, 782 in brain, 715,771,782 in caudate slices, 421 in chronic barbital treat
ment, 809
977
in hippocampus, 716,782 in mammalian skeletal
muscle, 2Q5 metabolism and ~ depolariza-
tion, 531 regulation of synthesis, 97 source of, 410 storage, 261.273 synthesis
and choline transport, 489,49~ and glucose, 421,922 and hypoxia, 443 in cholinergic nerve
nerve terminals, 97 in isolated heart, 159
ACh release A23l87 on, 580 4-aminopyridine on, 293 and choline transport, 489 and Na-K ATPase, 187,521 atropine on! 169,184,580 black widow spider venom on, 224 Ca++ on, 184, 188 carbachol on, 292,580 cations on, 188 p-chloromercuribenzoate on, 188 chloropromazine on, 188 choline on, 174,455 C1- on, 458 DFP on, 292 digoxin on, 188 electrical stimulation on,
169, 766 ethanol on, 188 N-ethy1male.imide on, 188 from central neurons, 169 from diaphragm, 455 from electric organ, 288 from hippocampal slices, 580 from isolated heart, 159 from myenteric plexus, 169. 177 from Schwann cells, 223 from superior cervical
ganglia, 455 from synaptosomes, 489,504,
521,579 from the retina, 555
978
GABA ont 763 K+ on, 169,187,580,766 mechanism of, 283 Mn++ on, 183 naloxone on, 184 nicotinic drugs on, 169 non quantal, 187,209 noradrenaline on, 526 ouabaine on, 187,224,293,580 oxotremorine on, 184, 580 quantal, 187,192,216 quinidine on, 188 regulation of, 224 scopolamine on, 170 tetrodotoxin on, 580 veratridine on, 580 vesicular, 307
ACh turnover and 69 tetrahydro
cannabino1s, 826 and oxotremorine, 782 during development, during
aging, 18,42 effect of drugs on, 715,874 in ganglia, 100 in hippocampus, 708,716,782 in PC12 cells, 138 vesicular, 506
ACh uptake, 301 AChE
after lesion of the n. basalis magnoce11u1aris, 667
and chronic barbital, 813 distribution in the brain, 723 -dopaminergic re1ationships,725 effect of 5-HT on, 741 from bovine red blood cells,750 in brain through phylogeny, 62 in cortical areas, 674 in denervated iris, 549 in denervated muscle, 387 in developing electric organ,50 in frog skeletal muscle, 197 inhibition of the iris, 569 inhibitors, 170, 325, 329, 402,
420,453,879,948 in hippocampus, 842 in neural crest, 2 in superior cervical gang1ion,128
SUBJECT INDEX
in thyroid deficiency, 78 molecular forms of, 847 separation from AChR, 325 staining for, 127,664 vesicular, 264
AChR see ACh receptors
ACh receptors see J;Iluscarinic see nicotinic
Adamantyl radical, 359 Adenosine
in nerve ending, 295 on ACh release, 293
Adrenal medulla enkephalins in, 144
Adrenoceptors, 784 Aging
of cholinergic synapse, 27 similarity with axotomy, 33
Alternation, spontaneous, 604 Alzheimer's disease, 929 Amino acids
in AChR, 329 2-Amino-2-methy1propanol
(2-AMP), 434 4-Aminopyridine
and ACh release, 293,874 and giant epp, 291 and norepinephrine turnover,874 binding to axonal membranes,372 in Eaton Lambert syndrome, 874 in Huntington's chorea, 871
Amphetamine effect on
ACh output, 688 ACh turnover in the
hippocampus, 710 on striatal ACh level, 734
Amphibia brain cholinergic
mechanisms in, 65 Analgesia
cholinergic, 860 Anatruxonium, 356 Antibody
against ACh receptors,333,343 Anticholinergic drugs
structure action relationship,351
SUBJECT INDEX
Antihistaminic, 362 Antimycin A, 448 Antinociception
and cholinomimetic drugs,795,833 and narcotic analgesics, 795 and procaine, 833 chelating agents on, 796 divalent cations on, 796 tests for, 796,833
ADAA, 606 Arecoline
and cortical arousal, 949 and dreaming, 949 the first REM period, 949 antinociceptive activity,795,835 in Huntington's chorea, 875
Apomorphine, 733 on ACh turnover in
hippocampus, 708 Ataxia
choline trials in, 873 ATP
-citrate lyase, 418 content in vesicles, 242 in vesicles,z26l
ATPase, 187,521 Atropine, 169, 357, 604, 833
and chronic barbital, 819 and QNB binding sites, 547 binding, 613
to axonal membranes, 372 effect on ACh release, 184,580 in myasthenia gravis, 336 in the brain, 589 in the eye, 547 on brain ACh, 453,783 on choline-induced increase
in homovanillic acid, 433 on striatal ACh, 734
Autoreceptors, 579 Axoaxonic synapse, 716,786 Axonal
membranes, 367 sprouting, 221 transport,
of AChE and BuChE, 389 of cholinephospho
glycerides, 377 Axotomy
and motor nerve sprouting, 221
changes in ganglionic synapses, 33
Azide on choline uptake, 135
Barbital
979
chronic treatment, 809,819 Betaine, 433,514 Bicuculline, 561,716,766
intraseptal, 708,827 Bird
brain cholinergic mechanisms in, 65
embryos, 85 Binding studies
see muscarinic receptor see nicotinic receptor
Bis-(thioacetoxy)aurate, 127 Black widow spider, 153,224 Brain nuclei
muscarinic receptor distribution in, 589
Broca's diagonal band nucleus, 676
3-Bromopyruvate, 420,480 BuChE
as a precursor of AChE, 130 in denervated iris, 549 in denervated muscle, 389 in superior cervical
ganglion, 128 S-Bungarotoxin (S-Btx), 249
and receptor isolation, 656 binding
in the brain, 640 sites, 343
changes with age, 34 development of, 11
effect on, 12 in adrenals, 151 in myasthenia gravis,334 in the eye, 544 on ACh release in
Torpedo, 292 with horseradish
peroxidase, 369 in denervated skeletal
muscle, 659
980
to axonal membranes, 369
Ca++ and antinociception, 803 and muscarinic receptors, 649 channel, 224 clearance, 273 D-pOO, 218 efflux, 525 -free solution, 523,557 on ACh release, 183,188,310 on choline uptake, 99 on GPC diesterase, 400 uptake, 277
cAMP, 601 in ganglia, 121,123
Cannabidiol, 826 Cannabis sativa, 826 Carbachol, 292,360,591,597,833
on ACh release, 580 Carbamylcholine, 368,549
and binding, 612 in myasthenia gravis, 336
Carbohydrates in AChR, 329
8-Carbolines on cholinergic mechanisms, 745
Carnitineacetyltransferase, 212 CAT
see cholineacetyltransferase Cations
on nociception, 796 Caudate nucleus
ACh level in, 773 choline level in, 773 GPC diesterase in, 398 -putamen complex, AChE in, 731 slices, ACh, acetyl-CoA,
choline levels in, 421 Cerebellum
and cAMP and cGMP levels, 604 nicotinic binding sites in, 643 through phylogeny, 70
cGMP, 601 Ch
see choline ChAr
see cholineacetyltransferase Chlorisondamine
effect on development, 12
SUBJECT INDEX
p-Chloromercuribenzene sulphonate, 523
p-Chloromercuribenzoate on ACh release, 188
p-Chlorophenylalanine, 798 4-Chloro-7-nitrobenzenfurazon
(NBD-Cl), 139 Chlorpromazine
on ACh release, 188 Cholesterol
in synaptic vesicles, 242 Choline
absorption of, 438 after lecithin, 943 and base exchange, 381 and chronic barbital, 821 and lithium therapy, 891 phospholipid synthesis, 378,385 arterovenous difference, 405 assay for, 894 blood cell level, 897 brain turnover rate, 412 deficient diet and
brain ACh, 452 effect on acetyl-CoA, 420
on ACh level, 420,453 on ACh synthesis, 162,317,
425,535 on dopamine synthesis, 413
free pool of, 503 from phospholipids, 495 hippocampal level, 788 in blood, 901 in clinical trials, 873 in the striatum, 734 level in chronic barbital
treatment, 809 low affinity transport, 893 metabolism
in guinea pig, 435 in rat, 435
on ACh release, 174 on brain cAMP, 601 on brain cGMP, 601 on muscarinic receptQrs.174, 874 plasma levels, 897 RBC/plasma ratio, 891 source of, 385,393,405 synthesis in brain, 393,405
SUBJECT INDEX
Cho1ineacety1transferase, 402,772 after lesion of the n. basalis
magnoce11u1aris, 666,675 and ACh synthesis, 426 and choline uptake, 482 distribution in the brain, 723 immunoreactive staining, 700 in brain through phylogeny, 62 in chronic barbital treatment,809 in ciliary ganglion, 4 in developing electric organ, 50 in hippocampus, 842 in human placenta, 91 in inbred strains of mice, 474 in skeletal muscle, 205 in the eye, 543 in thyroid deficiency, 78
Choline analogs, 475 and electrostatic potentials,475 and free hydroxyl group, 475 on ACh synthesis, 434 uptake, 99,274,308
Choline deficient diet, 452 Choline dehydrogenase, 435 Choline efflux, 493,504,534 Choline kinase
and hemicholinium-3, 401 Choline phospho glycerides
as source of choline, 377,385 axonal transport of, 377 synthesis in perikarya, 377
Choline transport and acetylation, 501 and ACh synthesis, 491,497 neuraminidase on, 518
Choline therapy in neurological disorders, 873
Choline uptake and ACh release, 458 and ACh synthesis, 456 and choline analogs, 97 and depolarization, 493 development in ciliary
ganglia, 3,14 effect of C1- on, 456
of oxotremorine on, 782 high affinity, 456,475 in aging synapses, 35 in chronic barbital
treatment, 809
981
in inbred strains of mice, 463 in nerve cultures, 511 in PC12 cells, 134 in sympathetic ganglia, 101 in thyroid deficiency, 78 kinetics of, 469,498,517 low affinity, 456
Cholinergic-adrenergic balance hypothesis in depression and mania, 948 Cholinergic agents see also cholinomimetics use of, 853
Cholinergic mechanisms chronic barbital on, 809 effect of S carbolines on,745 in pupillary diameter, 949 in REM sleep, 949 in temperature regulation,949
Cholinergic-monoaminergic interactions, 723,781
Cholinergic pathways, 671,680, 715,777 ,786 septal-hippocampal, 705
Cholinergic systems anatomical organization of,663 in memory and learning, 859 mapping of, 695
Cholinomimetic agents and antinociceptive
activity, 795 and human memory, 929 and nociception, 833 and sleep studies, 949 and spontaneous alternation,604 in primary effective il1ness,947
Chromaffin cells, 145 Ciliary body, 543 Ciliary ganglion, 377 Cingulum, 718 Cirraso1, 325 Citrate
in ACh synthesis, 415 Citric acid cycle
and ACh synthesis, 448 Cl-
and ACh release, 458 and high affinity choline
uptake, 456
982
Concanavalin A, 226 Cooperativity
negative, 650 Cooper thiocholine (CuThCh)
histochemical method, 128 Cornea
ACh and choline acetyltransferase in, 542
choline uptake in, 543 Corneal blinking
and cholinomimetics, 833 Cortex, cerebral
AChE activity in, 674 ACh output from, 690 cAMP level in, 602 cGMP level in, 602 cholineacetyltransferase in,675 cholinergic systems in, 665 muscarinic receptors in, 649 nicotinic binding sites in, 643
Cortical intrinsic cholinergic neurons, 681
Cortical cholinergic afferent pathway, 673
Crotoxin, 249 Curare-like agents, 351-365 Cyanide sodium, 420 Cyclobutonium, 356 Cyclostomes
cholinergic mechanisms in, 65 Cytochrome C oxidase, 264
D-600, 218 Deanol
see dimethylaminoethanol Decadonium, 357 Decamethonium, 360 Dementia
choline trials in, 873 Depressive illness, 947
and blood choline levels, 905 and cholinergic agents, 861
Development of cholinergic enzymes, 4
Dexetimide, 613 DFP, 290,292,847,948 Diadonium, 357 N'-N'-Dicyclohexylcarbodi-
imide, 139 Diencephalon
through phylogeny, 71
SUBJECT INDEX
Diethyl, dimethylpyrophosphonate, 207
Diethyldithiocarbamate, 798 3,3'-Diethylthiodicarbocyanine
(diS-C2[5]), 317 Digoxin, 188 Dimethylaminoethanol, 475
(DMAE) , 437 on choline metabolism, 435
1,1-Dimethyl-3-hydroxypiperidine, 475
3,3-Dipentyl-2,2'-oxocarbocyanine, 525
Diphenhydramine, 362 4-Diphenylacetyl-N-methyl
piperidinemethiodide, 595 Diphenylcyclobutanedicarboxylic
acids, 351-365 4-Dipyrrolidino-2-butyne, 621
see tremorine Dopamine, 784,803,875
and AChE in substantia nigra,727 choline on, 429 effect on adenylate cyclase
in ganglia, 120 L-DOPA
effect on striatal ACh level, 734
Dreaming and cholinomimetics, 949
DSP-4, 784
EA0170l, 948 Eaton-Lambert syndrome
and 4-aminopyridine, 874 Echothiophate, 545 EGTA, 419,506,523,803 Electric organ, 218,238,242,
249,261,326 Electroplaque potential, 288 Electroretinography, 556 Electrostatic potential,
and choline analogs, 475 Encephalopathies,
and cholinergic disfunction,92l Endocytosis, 261 S-Endorphin, 716 Enkepha1ins, 833
effect on ganglionic transmission, 112 in adrena1s, 144
SUBJECT INDEX
Entorhina1 cortex afferents, 676 EPSP, 110, 112 Error
heteroscedastic and homoscedastic, 470
Eserine see physostigmine
Ethanol on ACh release, 188 on ACh synthesis in the iris,548
Ethanolamine, 405 Ethorphine, 149 N-Ethy1ma1eimide
and muscarinic receptor binding, 614
on ACh release, 188 Exocytosis, 495
transmitter release from vesicles, 187,261
Extensor digitorum longus, 222 Eye
cholinergic system in, 541 in cup preparation, 556
Fab, 343 False cholinergic
transmitters, 274,307,475 FCCP, 137 Feedback inhibition, 169, 782 Fenf1uramine, 781 Fimbria-fornix, 715 FLA-63, 783 Fluphenazine
on brain ACh, 455 Forebrain
GPC-diesterase, 398 Free hydroxyl group
in choline uptake, 475 Frog sartorius, 225
GABA and ACh interaction, 717,771 in hippocampus, 786 in olfactory bulb, 682 interneurons in septum, 719 on ACh release, 560,763 on neurons in the septum, 828
GABAergic agents, 715,764,773 Gallamine, 324
983
Gallamine ami.de amine inhibitor, 326
Ganglia ACh synthesis in, 97 chick ciliary development, 1 ciliary, 570 effect of black widow
venom on, 157 Ganglion of Remak in
cholinergic differenti.ation, 3 Gang1iosides, 221
and cholinergic enzymes, 841 Gilles de 1a Tourette syndrome
blood choline levels in, 910 GHa, 787
cultures of, 518 G1icera convo1uta venom, 215 Globus pa11idus
ACh output, 690 choline uptake, 685 lesion, effect on cortical
cho1ineacety1transferase, 668,685
Glucose in ACh synthesis, 416,443,491,
922 Glutamate, 875
high affinity uptake, 665 Glutamic acid decarboxylase
in the cerebral cortex, 665 Glutamine, 317 G1ycerophosphocho1ine, 395 G1ycerophosphocho1inephospho-
diesterase cations on, 399 in brain, 393 . inhibitors of, 400
Glycerol, 378 Gpp(NH)p, 611 Gramicidin D, 314 Growth medium
(eagle), 514 Guanine nuc1eotides,
and muscle receptors, 597,609 Guanylate cyclase, 601,716 5 '-Guany1y1imidodiphosphate, 597 Guinea pig
brain cortex, 308 ileum, 236,609
984
Haloperidol, 604 effect on ACh turnover, 708
on striatal ACh level, 734 HC-3
see hemicho1inium-3 Head drop, 353,354,355 Heart
ACh synthesis, 159 development in chick embryos,86 muscarinic receptors in, 590
Hemicho1inium-3, 99,135,161,170, 301,400,402,476,482,493,501,772
Hexobarbital in barbiturate abstinence, 819
Hill plot, 547 Hippocampus
ACh level in, 716,782 ACh release from, 782 ACh turnover in, 708,716,782 afferents to, 782 and septal lesions, 842 and tetrahydrocannabinol, 825 high affinity choline uptake
in, 782 innervation, 710 nicotinic receptors in, 640 slices, ACh release from, 580
Homarus americanus axons, 369 Homocho1ine, 475
uptake, 100, 102 Horseradish peroxidase, 673
transport by cholinergic neurons in the cortex, 670
5-HT and AChE, 741 see also serotonin
Huntington, George, 871 Huntington's chorea
and 4-aminopyridine, 871 and arecoline, 875 and choline therapy, 871 and neuroleptic drugs, 874 and neuronal degeneration, 875 and neurotransmitter
interactions, 875 and striatal cholinergic
liypofunction, 871 N-(40Hydroxybuty1)-M,N,N-tri
methy1ammonium, 99,475
SUBJECT INDEX
(-)-Hydroxy citrate, 418 6-Hydroxydopamine, 711,772
effect on ACh turnover, 708 Hypoglycemia, 925 Hypothalamus, 716
nicotinic binding sites in,643 Hypoxia
histotoxic, 443,923 hypoxic, 444,923
IgG, 343 in myastenic patients, 334
Indo1eamines and cholinergic mechanisms, 739
Iodoacetate and choline uptake, 135
Ions effect on muscarinic receptors,
647 Iris
AChE inhibition in, 569 cholinergic system in, 541 development of cholinergic
innervation, 1 Isobuty1-1-methy1xanthine, 400 Isoniazid, 605
K+, 188,525 on ACh release, 580 on ACh synthesis, 531
Kainic acid, 777,787,788 and cholinergic neurons, 665
KNC and ACh synthesis, 444
Kinetic coupling between choline and
ACh synthesis, 489 Kynurenine, 756
Lacrimal glands muscarinic binding sites in,596
Lactate dehydrogenase, 264 Lantanum, 209,224,803 Learning
and cholinergic system, 859 Lecithin
and ACh synthesis, 427 effect on memory, 937
on plasma choline 1eve1s,943 see also phosphatidy1cho1ine
SUBJECT INDEX
Leptocurares, 324 Levetimide, 613 Libinia emarginata
axons, 369 Lidocaine, 372 Light
effect on ACh release, 555 Lineweaver-Burke plot, 499 Lithium
assay for, 894 blood cell/plasma ratio, 898 plasma level in therapy, 898 RBC level in therapy, 898 treatment and blood choline
levels, 910 Locus ceru1eus, 781
AChE-noradrenergic relationships in, 735
Lysolecithin, 256,405 Lysophosphatidy1serine, 601
Magnoce11u1ar nuclei of the substantia innominata, 673
3H-4-(N-Ma1eimido)benzyltri-methy1ammonium (MBTA), 374
Mania, 947 Marijuana, 825 Mass spectrometry, 497,532,715,827 Mebhydro1ine, 362 Mecamylamine, 803 Medulla oblongata
through phylogeny, 70 Membrane fluidity, 257 Membrane transport systems
and neurotoxins, 249 Memory
and cholinergic system, 859 and cholinomimetic agents, 929 effect of lecithin on, 937
Mepp, 223,343 Mesencephalon
through phylogeny, 71 Metabolic inhibitors
in ACh synthesis, 420 Methionine, 405 Methy1atropine, 803,833 B-Methy1choline, 803 Methy1dioxo1ane, 613 Methy1isopropy1fluorophosphate,325
985
a-Methylparatyrosine, 783,798 N-Methyl-4-piperidinylbenzi1ate
as a muscarinic ligand, 647 N-Methy1scopolamine, 591,595,950 Methy1sergide, 767 Mg++, 400,493,506,557 MIPF, 325 Mitochondria, 264,383 Mitochondrial fraction
choline incorporation in, 516 Mn++, 183 Modulatory processes, 715 Monoethy1cho1ine, 475 Morphine, 149,177,796,835 Motoneuron sprouting, 221 Motor cortex, 676 Motor disfunction
and cholinergic drugs, 856 a-MSH
on hippocampal ACh turnover,718 Muscarinic receptors
agonist of, 613 and guanine nuc1eotides, 609 and N-ethylma1eimide, 614 agonist of, 613 autoreceptors, 579 binding, 609 binding states of, 595,609 effect of ions on, 647 in chronic barbital
treatment, 809 in myenteric plexus, 169 in the eye, 541 in the iris, 571 kinetic constant of, 649 localization by radio-
histochemistry, 587 presynaptic, 169,579,784 regulation of, 609 supersensitivity, 9.50
Muscimol, 717,772 effect on ACh turnover 708 intraseptal, 827 '
Muscle AChE in, 197 and antibody localization,344 cell culture, 343 ChAT activity in, 205 ciliary, 544
986
denervated, 387,659 mammalian, skeletal, ACh
content, 205 Myasthenia gravis, 333,343,879
cholinergic drugs in, 854 Myastenic
immunoglobulins, 343 motor endp1ates, 333 serum, 333
Myenteric plexus ACh release from, 169,175 false transmitters,
uptake in, 308 muscarinic receptors in, 169 synaptic vesicles from, 235
Myocardium development in chick embryos, 85
Na+ channel, and neurotoxins, 249 on ACh release, 188 on choline uptake, 478
Naloxone, 184,796,835 4-C-1-Naphthy1viny1)
pyridine, 212,432 Narcine brasiliensis, 241
synaptic vesicles, 314 Narcotic antagonists
and antinociception, 796,834 Neostigmine
pharmacokinetics of, 879 Neostriata1 slices, 531 Neural crest, 2,3 Neuraminidase, 518 Neuroleptic drugs
in Huntington's chorea, 874 Neuromuscular
junction, 221 preparation, 223
frog, 215,344 transmission, 223,343,353
Neuronal cultures, 511 Neuropeptides, 875
and hippocampal ACh, 715 Neurotoxins, 249 Nicotine, 372
binding in the brain, 641 Nicotinic receptors
antibody against, 333,343 composition of, 329
SUBJECT INDEX
in denervated skeletal muscle, 659
in developing electric organ, 50
interaction with opiates, 151 in the brain, 639 in the eye, 541 separation from AChE, 325 structure of, 653
Nigericin, 137,318 Nomifensine
on ACh turnover, 710 Noradrenaline, 803
and 4-aminopyridine, 874 content in hippocampus, 788 effect on ACh release, 526
on cAMP levels in gang1ia,121 in the iris, 571
Noradrenergic pathways, 681,782 Norepinephrine
see noradrenaline Notechis II-S, 249 Notexin, 249 Nucleus basalis
magnoce11u1aris, 666,673 of Maynert, 668
Obidoxim, 329 Olfactory bulb, 699 Olfactory cortex, afferents, 675 Oligomycin, 137 Opiates
action on adrenal, 148 receptors, 149
Ouabaine, 293 on ACh release, 224,580 on rubidium uptake, 522
Oxotremorine and ACh turnover, 782 and choline uptake, 782 and postsynaptic mechanism,782 and presynaptic mechanism, 169 and QNB binding, 613 antinociceptive activity,
795,833 effect on ACh release, 169,182,
580,782 on hippocampal ACh and
choline levels, 782
SUBJECT INDEX
on striatal ACh and choline levels, 734
in the eye, 545 structure-activity relation
ships, 621 Oxygen
and ACh synthesis, 444 Oxythiamine, 288
Pachycurares, 324 Pain mechanisms, 860 Pancurone, 874,880 Paraoxon, 420,427,453,500,847 Pathways
cholinergic, 673,680,715,777, 786
dopaminergic, 777 glutamatergic, 777 noradrenergic, 681,782 peptidergic, 716 serotoninergic, 777,782
PCl2 cells, l33 Penfluridol, 783 Peptidergic septal afferents, 716 Perforant pathway, 710 PGEl
adenylate cyclase in ganglia, effect on, 120
Phenoxybenzamine, 767,783 on ACh turnover, 710
Phentolamine, 766 Phenylmethanesulfonylfluoride,324 Pheochromocytoma, 133 Phosphatidylcholine, 393,405,873 Phospholine
see echothiophate Phospholipids, 377,378,601
and choline concentration, 495 in vesicles
content, 242 turnover, 383
Phospholipon, 939 Phosphorylcholine, 437,513,873 Physostigmine
and antinociceptive activity, 795,833
and cortical arousal, 949 and dreaming, 949 and first REM period, 949 and hypoglycemia, 925
987
and memory, 933 and mouse behavior, 858 and thiamine deficiency, 925 binding to axonal
membranes, 292,372 in Huntington's chorea, 875 on ACh release on brain cAMP, 601 on brain cGMP, 601 similarity with a tryptamine
deriva tive, 756 Picrotoxin, 561,766,775 Pilocarpine, 950
and binding, 613 antinociceptive activity,
795,835 Pimozide, 783
effect on striatal ACh level, 734
Pirenzepine binding to tissues, 596,650
Placenta ChAT from, 94
Plasma choline, 871,897 Positron emitting tomography,875 Pralidoxime
and AChE reactivation, 850 Presynaptic muscarinic
receptor, 169,784 Primary affective illness
and cholinomimetics, 947 and lithium therapy, 893 REC/plasma choline, ratio in,
897 Procaine, 362,372,833 Prolactin, 717,947 Promethazine, 362 Propionylcholinesterase
(PrChE), 131 Propranolol, 783 Propylbenzilcholine, 595 Propylthiouracil
effect on ChAT and choline uptake, 78
Psychiatric diseases and blood choline, 901
Pyridostigmine pharmacokinetics of, 879
Pyrithiamine, 925
988
N-(4-Pyrro1idino-2-butynyl)-2-pyrrolidone, 621 see oxotremorine
Pyrro1idinecholine, 475 Pupillary function, 572 Pyruvate
in ACh synthesis, 415,501
Quinidine, 188,293 (±)Quinuclidinylbenzilate
(QNB), 364,372,544,584,647, 613,772
Quipazine, 787
Radiohistochemistry of muscarinic receptors, 587
Receptogenesis, 11 Receptor
binding., 575 regulation, 544
Red blood cells human, choline content, 897
Regeneration-reinnervation, 221 REM sleep, 947
and arecoline, 949 Reptiles
brain cholinergic mechanisms in, 65
Reserpine, 604,782,796 Retina
ACh release from, 555 synthesis in, 543
Rosenblueth's phenomenon, 105 Rubidium uptake, 522
Scatchard plot, 545,590 Scopolamine, 950
and mouse behavior, 858 on ACh release, 169 on binding, 613 on brain cAMP, 601 on brain cGMP, 601 on T-maze, 604
Schizophrenia and cholinergic agents, 861
Schwann cells, 369 ACh release from, 223
Seizures on cholinergic mechanisms, 809
SUBJECT INDEX
Septal-hippocampal cholinergic pathWay, 680,715
neuropeptides on, 715 Septum, 699,705
lesions, effect of gangl1.osides, 841
Serotonin, 803 in hippocampus, 788 in the striatum, 730 see also 5-HT
Serotoninergic pathways, 782 Sleep
and cholinergic drugs, 856,949 Smooth endoplasmic reticulum
and choline phosphoglyceride axonal transport, 381
Soman, 573 Somatostatin, 710 Somite, 86 Sphingomyelin, 393 Spiroperidol, 766 Storage granules, 139 Striatum
cholinergic-monoaminergic relationships in, 728
cholinergic neurons in, 670 nicotinic binding sites in,643
Substance P, 716 effect on ganglionic
transmission, 110 Substantia nigra
AChE in, 725 Succinylcholine, 360 Sulfocholine, 475 Superhigh affinity
of muscarinic receptors,590,609 Supersensitivity, 545
and chronic scopolamine, 950 Synaptic vesicles, 216
ACh content in, 294 storage in, 273 uptake into, 301
active, 274 biochemical composition,242-268 from myenteric plexus, 235 from narcine, 313 from Torpedo, 242,261,301 heterogeneity, 261
subpopulation, 274
SUBJECT INDEX
transmembrane potential, 320 turnover, 383
Synaptosomes, 239,250,447,469, 476,492
Synaptogenesis, 1
Taipoxin, 249 Tardive dyskinesia
choline trials in, 873 Tectum
through phylogeny, 70 Telencephalon
through phylogeny, 71 Te1eosts
brain cholinergic mechanisms in, 65
Tetrabenazine, 796 ~9 Tetrahydrocannabino1s
effect on ACh turnover, 826 Tetrahydroharmane
on ACh activity, 748 Tetrapheny1boron, 416 Tetradotoxin, 190,765
binding to axonal membranes,372 on ACh release, 527,580
Theophylline, 293,400 Thiamine
deficiency, 925 on ACh release, 293
Thyroid deficiency and ChAT activity, 78 and choline uptake, 78
Tolerance to barbital, 809 to scopolamine, 950
Torpedo ca1ifornica nicotinic receptors in, 241,654
Torpedo marmorata, 249 AChE from, 50
989
ACh release from, 218,238,242, 261,287,309
ChAT from, 50 developing electric organ,
electric organ discharge, 52 nicotinic receptors, 50 synaptic vesicles, 238,301,
313,326 Torpedo nobi1iana, 374 Transmitters
in the iris, 571 Tremor, 624 Tremorine, 621
antinociceptive activity, 795,833
Triethy1cho1ine, uptake, 100,475 N,N,N-Trimethy1-N-Prop-2-)
yny1ammonium, 475,476,483 [3H] Tripheny1methy1phosphonium
Br (TMTP), 314 Truxi11ic acids, 351-365 TUbercidine, 293 d-Tubocurarine, 292,336,364,370
binding sites in the brain,640 Tyrosine hydroxylase, 787
Vagus, stimulation effect on ACh release, 160
Valinomycin, 137,315 Veratridine, 523
binding to axonal membranes, 372
on ACh release, 580 on choline uptake, 493
Videotape recording of patients, 874
Withdrawal, barbital, 809